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diopathic Ventricular
ibrillation “Le Syndrome
’Haïssaguerre” and the
ear of J Waves*
ami Viskin, MD
el Aviv, Israel
diopathic ventricular fibrillation (VF) is a disease of
nknown etiology but with well described clinical (1) and
lectrophysiologic (2,3) characteristics. Briefly, young
dults present with syncope or cardiac arrest due to
olymorphic ventricular tachyarrhythmias in the absence
f structural heart disease or identifiable channelopathies
4). The spontaneous arrhythmias are not related to stress
nd are invariably triggered by narrow-complex ventric-
lar extrasystoles with very short coupling intervals (5,6).
See page 612
Haïssaguerre et al. (7) recently reported that 1 of 3
atients with idiopathic VF has an intriguing electrocar-
iogram (ECG) that demonstrates J waves and ST-
egment elevation in the inferolateral leads (the “early
epolarization” pattern). In this issue of the Journal,
aïssaguerre et al. (8) report that “idiopathic VF patients
ith J waves” tend to develop arrhythmic storms that
espond solely to isoproterenol and quinidine.
e Syndrome d’Haı¨ssaguerre
atients with “idiopathic VF and early repolarization”
ere more often male subjects, had shorter QT intervals,
nd had arrhythmias more frequently than idiopathic VF
atients with a normal ECG (7). High-amplitude J waves
onferred a higher risk for arrhythmic storm, and tran-
ient augmentation of the J-wave amplitude preceded the
nset of VF (7,8). These observations were confirmed by
am et al. (9).
VF storms occur in 18% of patients with symptomatic
rugada syndrome (10) and occurred in 13% of idio-
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iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.c
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niversity, Tel Aviv, Israel.athic VF patients in this series (8). The VF storms of
rugada syndrome and idiopathic VF share some char-
cteristics: VF clusters are sometimes triggered by fever,
umerous VF episodes originate from the same myocar-
ial area, and the recurrent arrhythmias are refractory to
onventional antiarrhythmic therapy, including beta-
lockers and intravenous amiodarone (8,10). Both con-
itions respond to intravenous isoproterenol (7–9,11),
robably because isoproterenol reduces the dispersion of
epolarization that enables the onset of VF (12). For all
e know, patients with “idiopathic VF and early repo-
arization” have a worse (rather than a different) form of
diopathic VF.
The disappointing response to verapamil reported by
aïssaguerre et al. (8) is noteworthy because verapamil
as the emergency treatment originally proposed for
short-coupled variant of torsade de pointes” (an arrhyth-
ia indistinguishable from idiopathic VF) (13). In an
nstructive case (14), verapamil abolished the short-
oupled extrasystoles that triggered VF (without prolong-
ng the very short ventricular refractory period), while
ifekalant prolonged the refractory period without sup-
ressing the triggers of arrhythmia (14). Nonetheless,
ailure of verapamil has also been the rule in our
xperience (3).
he Fall and Rise of Quinidine
he excellent short- and long-term response to quinidine
eported by Haïssaguerre et al. (8) should come as no
urprise. Back in 1929, the first published case of idio-
athic VF also involved an arrhythmic storm that re-
ponded to quinidine (15). For more than 2 decades (2),
elhassen (2,3,16–18) has led the way of quinidine
herapy for idiopathic VF and Brugada syndrome with
xcellent results. Quinidine is also consistently effective
uring arrhythmic storms due to Brugada syndrome (11).
n congenital short QT syndrome (a condition similar to
diopathic VF in many ways) (19), only quinidine (but
ot sotalol, flecainide, or ibutilide) normalizes the abnor-
ally short ventricular refractory period and prevents the
nduction of VF (20). A prominent transient outward
otassium current (ITo) plays a major role in arrhythmo-
enesis in these “J-wave syndromes” (21), and the bene-
cial effects of quinidine are probably mediated by ITo
lockade (21).
Ironically, the realization that quinidine is often the
nly effective drug for VF storms comes at a time when it
s increasingly difficult to obtain quinidine supplies (22).
straZeneca, one of its main manufacturers, recently
eased production (23). As superbly summarized by
ilde and Langendijk (24), the disappearance of antiar-
hythmic drugs like procainamide, mexiletine, and quin-
dine was driven by revenue issues and though affecting
nly a small number of patients, it may have dire
onsequences for them. Hopefully, this report by Haïs-
s
n
a
W
J
p
a
p
p
t
t
b
d
N
s
“
a
c
d
H
h
s
p
l
d
m
s
l
d
p
g
o
o
w
T
i
m
d
i
w
t
i
t
s
t
a
w
R
m
A
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
621JACC Vol. 53, No. 7, 2009 Viskin
February 17, 2009:620–2 Idiopathic VFaguerre et al. (8) will prompt health care systems to
egotiate with the pharmaceutical industry to ensure the
vailability of quinidine.
ho Is Afraid of the Big Bad J-Wave?
waves are commonly observed in healthy individuals,
redominantly in young males (25) and especially among
thletes (26). These age- and sex-related differences
ersist during autonomic blockade with atropine and
ropranolol (25), suggesting that intrinsic differences in
he contour of the myocardial action potential, secondary
o sex-related diversity in ion-current density mediated
y androgenic receptors (27), affect the size of J waves.
The association between J waves and idiopathic VF
escribed by Haïssaguerre et al. (7) was confirmed by
am et al. (9) and our group (26) and is probably here to
tay. In fact, the Haissaguerre et al. study (7) triggered a
fear of J waves.” Electrophysiologists may be consulted
bout the arrhythmic-death risk after an incidental dis-
overy of J waves. Unfortunately, we do not know how to
istinguish “arrhythmogenic” from “normal” J waves.
aïssaguerre et al. (7) observed that patients with VF
ave J waves with larger amplitude than matched control
ubjects, and we noticed a similar trend (26). Also,
atients with idiopathic VF have QT intervals in the
ower normal range (19) that fail to prolong adequately
uring heart rate slowing (28). However, there is too
uch overlapping between VF patients and control
ubjects in terms of J-wave amplitude (7,26), J-wave
ocation (26), and QT intervals to permit an accurate
iagnosis. Finally, arrhythmias in idiopathic VF are not
rovocable by exercise but may be induced with pro-
rammed ventricular stimulation (1). Thus, electrophysi-
logists may be tempted to recommend electrophysi-
logic studies for risk stratification of patients with J
aves (like current practices in Brugada syndrome) (29).
hat would be unadvisable because the value of VF
nduction for predicting spontaneous arrhythmias re-
ains contentious (30). Since idiopathic VF is a rare
isease, and there are no tests for confirming or excluding
t in the asymptomatic patient, asymptomatic patients
ith J waves should not undergo further testing. During
he last decade, numerous young and otherwise healthy
ndividuals worldwide underwent prophylactic implanta-
ion of defibrillators because of “asymptomatic Brugada
yndrome with inducible VF” (31). Yet, the consequences of
hat policy—in terms of adverse events—are only now being
ppreciated (30). Hopefully, patients with “asymptomatic J
aves and inducible VF” will not share the same fate.
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